Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

NCT03727724 | Completed Phase 2

• 1 other identifier: M18ACX
• Study Type: interventional
• Target: 37
• Locations: 1 country
• Sites: 4

Brief Summary

This is a single arm open-label multi-center phase II study, investigating disease control rate after 18 weeks of treatment with afatinib/cetuximab combination therapy in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion.

Conditions

Carcinoma, Non-Small-Cell Lung

Outcome Measures

Primary Outcomes (1)

• Disease control rate after 18 weeks

  To determine the disease control rate at 18 weeks of afatinib and cetuximab treatment in patients with NSCLC harboring an EGFR exon 20 insertion mutation.

  18 weeks

Secondary Outcomes (5)

• Objective tumor response

  Scans every 6 weeks until tumor progression, start of another treatment or death.

• Safety (intensity and incidence of adverse events)

  Up to 30 days after last study drug intake.

• Duration of response (DOR)

  Scans every 6 weeks until tumor progression

• Progression free survival

  Until progression, every 6 weeks up to progression

• Overall survival

  Every 6 weeks up to death

Other Outcomes (1)

• Genetic profiling to assess predictors of response and resistance - circulating free (cf)DNA

  At baseline, cycle 1 day 15 and at treatment discontinuation (expected 6 months after start)

Study Arms (1)

Afatinib plus cetuximab

EXPERIMENTAL

Afatinib, 40 mg once daily, orally. Cetuximab, 500 mg/m² intravenously, every 2 weeks. Treatment will be continued until tumor progression (according RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs.

Drug: Afatinib; Drug: Cetuximab

Interventions

Afatinib DRUG

Tablet

Afatinib plus cetuximab

Cetuximab DRUG

Injection

Afatinib plus cetuximab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Pathologically or cytologically confirmed stage IV non-small cell lung cancer, harboring an EGFR exon 20 insertion mutation.
• years or older at time of study entry.
• Life expectancy of at least three months.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix 1).
• Measurable disease, according to RECIST 1.1.
• At baseline adequate fresh or archived tissue from a histological biopsy or a cellblock obtained by fine needle aspiration of a tumor lesion that is not radiated prior to biopsy, must be available. Baseline tissue samples must have been obtained after the last line of systemic therapy prior to study entry.
• Adequate normal organ and marrow function as defined below:
• Absolute leukocyte count ≥ 3 x 109/L (\> 3000 per mm3)
• Platelet count ≥ 75 x 109/L (\>75,000 per mm3)
• Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≤ 3 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤ 5x upper limit of normal (ULN).
• Serum creatinine clearance \>30 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance.
• Women of child-bearing potential: these subjects must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment and agree to use highly effective contraception, as defined in section 5.2.2, from 7 days prior to enrollment, throughout the treatment period and for seven months after completion of the treatment with cetuximab.
• Males must agree to take appropriate precautions to avoid fathering a child from the first dose of study treatment through 3 months after the final administration of investigational drugs.
• Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
• Ability to give written informed consent before patient registration.

You may not qualify if:

• Participation in another clinical study with an investigational product during the last 2 weeks.
• Prior treatment with EGFR targeting antibodies (prior treatment with EGFR TKI's is allowed).
• Other active malignancy.
• History of hypersensitivity to afatinib or cetuximab.
• Major surgery (excluding diagnostic procedures e.g. mediastinoscopy or video assisted thoracic surgery (VATS) biopsy) within 28 days of the start of study treatment.
• Radiotherapy less than two weeks prior to the start of study treatment.
• Symptomatic brain metastases.
• Breast feeding is not allowed during study treatment.
• Uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, myocardial infarction within 12 months prior to the study entry, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent. Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety and anti-tumor activity of the test drugs.

Sponsors & Collaborators

• The Netherlands Cancer Institute: lead
• Boehringer Ingelheim: collaborator
• Merck Serono International SA: collaborator

Study Sites (4)

Antoni van Leeuwenhoek

Amsterdam, North Holland, 1066 CX, Netherlands

Location

VU Medical Center

Amsterdam, 1007 MB, Netherlands

Location

University Medical Center Groningen

Groningen, 9713 GZ, Netherlands

Location

Maastricht UMC+

Maastricht, 6229 HX, Netherlands

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Afatinib; Cetuximab

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Amides; Organic Chemicals; Quinazolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• J de Langen, MD, PhD

  NKI-AvL

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 3, 2018
• First Posted: November 1, 2018
• Study Start: December 4, 2018
• Primary Completion: September 6, 2022
• Study Completion: September 6, 2022
• Last Updated: October 18, 2023

Record last verified: 2023-10

Locations

NL (4)